Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John Paul Runyon"'
Autor:
Todd J. Lorenz, Neal S. Kleiman, James E. Tcheng, Michael M. Kitt, Ian C. Gilchrist, Lisa K. Jennings, J.Conor O’Shea, Teddy Kosoglou, John Paul Runyon, Charles J. Davidson, David Talley, Frank V. Aguirre
Publikováno v:
Circulation. 104:406-411
Background Pharmacodynamics of eptifibatide, a cyclic heptapeptide antagonist of platelet glycoprotein IIb/IIIa, are substantially altered by anticoagulants that chelate calcium, resulting in overestimation ex vivo of the in vivo effects of this agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f05a18e44b6d901fe001a489ed3ba131
https://doi.org/10.1161/hc2901.093504
https://doi.org/10.1161/hc2901.093504
Autor:
Charles W. Abbottsmith, Thomas M. Broderick, Douglas Cocks, David D. Whang, Dean J. Kereiakes, Eli M. Roth, Charles R. Hattemer, Robert L. Obenchain, Mark McDonald, Andrew L. Smith, Thomas M. Shimshak, John F. Schneider, John Paul Runyon, Beth L. Barber
Publikováno v:
American Heart Journal. 140:603-610
Placebo-controlled randomized trials of platelet glycoprotein (GP) IIb/IIIa blockade during percutaneous coronary intervention have demonstrated efficacy of these agents for reducing the risk of periprocedural ischemic events. However, cost-effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc759113f5c1822d9679a3ad27f7f80
https://doi.org/10.1067/mhj.2000.109647
https://doi.org/10.1067/mhj.2000.109647
Publikováno v:
The American Journal of Cardiology. 85:23-31
Platelet glycoprotein (GP) IIb/IIIa receptor blockade improves clinical outcomes after percutaneous coronary intervention (PCI) and for patients who present with non-ST-segment elevation acute coronary syndromes. Although this class of therapeutic ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b9c3f8caf43d8eccffb7d253c3c5584
https://doi.org/10.1016/s0002-9149(00)00876-6
https://doi.org/10.1016/s0002-9149(00)00876-6
Autor:
Thomas M. Broderick, Roger J. Dreiling, Eric J. Topol, Robert J. Anders, John Paul Runyon, Dean J. Kereiakes, Linda C. Anderson, Gary L. Hantsbarger, James J. Ferguson, Charles W. Abbottsmith, Brian Bryzinski, Neal S. Kleiman, A. R. Zaki Masud
Publikováno v:
Circulation. 98:1268-1278
Background —Parenteral administration of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor blockers can reduce ischemic complications of coronary angioplasty. Orally active GP IIb/IIIa blockers may allow more sustained receptor antagonism with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796d322ce978cf9627d2e269dddc6dad
https://doi.org/10.1161/01.cir.98.13.1268
https://doi.org/10.1161/01.cir.98.13.1268
Autor:
Robert M. Schainfeld, Farrell O. Mendelsohn, Vickie R. Driver, John Paul Runyon, Tina Thorne, Bret N. Wiechmann, Paul Huang, Melhem J. Sharafuddin, Tara Weistroffer, Kenneth Story, Charles S. Thompson, William A. Marston, Candice Junge, Victoria Teodorescu, Teresa L. Carman, Douglas W. Losordo, Meredith Millay, Suhail Dohad, Melina R. Kibbe, Larry W. Kraiss
Background— Critical limb ischemia portends a risk of major amputation of 25% to 35% within 1 year of diagnosis. Preclinical studies provide evidence that intramuscular injection of autologous CD34+ cells improves limb perfusion and reduces amputat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee013c2aebbb3106996989d9e1b6c873
Autor:
Peter S. Fail, Jack Chamberlin, Craig M. Walker, Lawrence A. Garcia, David E. Allie, David E. Kandzari, Stefan Kiesz, Venkatesh G. Ramaiah, Joseph Cardenas, John Paul Runyon, Maurice Solis, Roger S. Gammon
Publikováno v:
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 13(5)
To determine midterm clinical outcomes among patients with lower extremity peripheral arterial disease who underwent revascularization with catheter-based plaque excision (PE).Between August 2003 and February 2005, 19 institutions participating in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db8ee5615bb75bbdacb1ca70b79adbb
https://pubmed.ncbi.nlm.nih.gov/17042658
https://pubmed.ncbi.nlm.nih.gov/17042658
Autor:
John J, Young, Daniel P, Marcus, Charles W, Abbottsmith, Thomas M, Broderick, Joseph K, Choo, John Paul, Runyon, John F, Schneider, Thomas M, Shimshak, Rodney P, Geier, Dean J, Kereiakes
Publikováno v:
The Journal of invasive cardiology. 15
Although randomized clinical trials have demonstrated efficacy of coronary irradiation versus placebo for the treatment of in-stent restenosis (ISR), durable long-term benefit in community practice is less well defined. From January 1, 2001, through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a5c2cfb4d62074b29bc6922350fdfd1
https://pubmed.ncbi.nlm.nih.gov/12668834
https://pubmed.ncbi.nlm.nih.gov/12668834
Autor:
John F. Schneider, Daniel A. Tramuta, Thomas M. Broderick, Charles R. Hattemer, John Paul Runyon, Thomas M. Shimshak, David D. Whang, Charles W. Abbottsmith, Eric J. Dippel, Dean J. Kereiakes, Eli M. Roth
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions. 52(3)
Coronary perforation is an uncommon but potentially life-threatening complication of percutaneous coronary intervention. The use of both atheroablative technologies for coronary intervention and adjunctive platelet glycoprotein blockade pharmacology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f76a37e013763de9fa0c014fc71fae8
https://pubmed.ncbi.nlm.nih.gov/11246237
https://pubmed.ncbi.nlm.nih.gov/11246237
Autor:
John F. Schneider, John Paul Runyon, David D. Whang, Dean J. Kereiakes, Michele N. Mueller, Thomas A. Shimshak, Eli M. Roth, Pam Lacock, Thomas M. Broderick, Charles W. Abbottsmith, Charles R. Hattemer
Publikováno v:
The American journal of cardiology. 84(4)
Adjunctive platelet glycoprotein IIb/IIIa blockade during percutaneous coronary intervention (PCI) reduces platelet-mediated adverse ischemic outcomes. Although abciximab, eptifibatide, and tirofiban have received U.S. Food and Drug Administration ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa0949be38b4f2a5c07cfd33d715014
https://pubmed.ncbi.nlm.nih.gov/10468074
https://pubmed.ncbi.nlm.nih.gov/10468074
Autor:
Robert J. Anders, Linda H. Martin, Nancy A. Higby, Thomas M. Broderick, Dean J. Kereiakes, Neal S. Kleiman, Gary L. Hantsbarger, Shawn McDonald, James J. Ferguson, John Paul Runyon
Publikováno v:
Circulation. 96(4)
Background Inhibition of platelet aggregation with parenteral glycoprotein (GP) IIb/IIIa receptor blockers can reduce the ischemic complications of angioplasty. Sustained efficacy and safety of protracted GP IIb/IIIa blockade with an orally administe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b16cbe04020f9f9eede08f6759fe407b
https://pubmed.ncbi.nlm.nih.gov/9286938
https://pubmed.ncbi.nlm.nih.gov/9286938